FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  BOGER JOSHUA S						2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC /								Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner				
						MA [ VRTX ]								X Officer (give				·
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED						3. Date of Earliest Transaction (Month/Day/Year) 06/27/2006								President & CEO				
130 WAVERLY STREET														5. Individual or Joint/Group Filing (Check Applicable				
(Street) CAMBRIDGE MA 02139					_								Line	X Form fi	Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State) (Zip)																		
		Ta	ble I - No	n-Deri	ivativ	e Se	ecuri	ties Ad	quired	l, Dis	posed o	f, or Ber	neficial	y Owned				
D. D					2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)		action (Instr.		ies Acquire Of (D) (Inst		Beneficially Owned Following		Form:	Direct Indirect Etr. 4)	Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D)	Price	Transact	Reported Transaction(s) (Instr. 3 and 4)		(	Instr. 4)
Common Stock 06/27						2006		М		11,880	) A	\$15.5	66 1,04	17,283		D		
Common Stock 06/2					27/200	7/2006				Т	11,880	) D	\$30.7	7 1,03	1,035,403		D	
Common Stock														207	7,500		1 1	shares in rust <sup>(2)</sup>
Common Stock														15	,979		I 4	101(k)
			Table II -								osed of, convertil			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,		ransaction ode (Instr.		of E		exercis on Date Day/Yea		of Securities		Derivative Security	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	e le s li liy l	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	ble	Expiration Date	Title	Amount or Number of Shares					
Stock	\$15.56	06/27/2006	1		Α			11 880	03/12/10	07(3)	12/11/2006	Common	11 880	\$0	1 996 5	31	D	1

## **Explanation of Responses:**

- 1. Transaction made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.
- $2. \ Shares \ held \ in \ trust \ for \ Dr. \ Boger's \ children. \ Dr. \ Boger \ disclaims \ beneficial \ ownership \ of \ such \ shares.$
- 3. Right to buy under 1994 Stock and Option Plan, vesting quarterly over 5 years from 12/12/1996.

## Remarks:

Kenneth S. Boger, Attorney-In-**Fact** 

\*\* Signature of Reporting Person

06/28/2006

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.